Liver hydrolysate attenuates the sickness behavior induced by concanavalin A in mice

被引：11

作者：

Nakagawasai, Osamu ^{[1
]}

Yamada, Kotaro ^{[2
]}

Nemoto, Wataru ^{[1
]}

Sato, Shin ^{[1
]}

Ogata, Yoshiki ^{[1
]}

Miya, Kohei ^{[1
]}

Sakurai, Hidetomo ^{[2
]}

Tan-No, Koichi ^{[1
]}

机构：

[1] Tohoku Pharmaceut Univ, Dept Pharmacol, Sendai, Miyagi 9818558, Japan

[2] Zeria Pharmaceut Co Ltd, Consumer Healthcare Prod Dev, Tokyo 1038351, Japan

来源：

JOURNAL OF PHARMACOLOGICAL SCIENCES | 2015年 / 127卷 / 04期

关键词：

Liver hydrolysate; Locomotor activity; Sickness behavior; ACTIVATION; DOPAMINE; MODEL;

D O I：

10.1016/j.jphs.2015.03.007

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Liver hydrolysate (LH) is used as a pharmaceutical agent in Japan, to enhance liver function. However, the effects of LH on sickness behavior are unknown. This study investigated the effect of LH on sickness behaviors, such as concanavalin A (ConA)-induced reduction of locomotor activity. ConA treatment significantly decreased locomotor activity. The striatal tyrosine hydroxylase (TH) levels were also significantly decreased following ConA treatment. The decreased locomotor activity and TH levels were significantly reversed by LH treatment. LH may prove beneficial for preventing sickness behavior following ConA treatment, at least in part, by activating TH in the striatum. (C) 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

引用

页码：489 / 492

页数：4

共 15 条

[1] Immune-neuro-endocrine interactions: Facts and hypotheses [J].

Besedovsky, HO ;

DelRey, A .

ENDOCRINE REVIEWS, 1996, 17 (01) :64-102

[2]

Boehm S, 1998, J NEUROCHEM, V71, P2421

[3] Nucleus accumbens shell and core dopamine: differential role in behavior and addiction [J].

Di Chiara, G .

BEHAVIOURAL BRAIN RESEARCH, 2002, 137 (1-2) :75-114

[4] 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside stimulates tyrosine hydroxylase activity and catecholamine secretion by activation of AMP-Activated protein kinase in PC12 cells [J].

Fukuda, T. ;

Ishii, K. ;

Nanmoku, T. ;

Isobe, K. ;

Kawakami, Y. ;

Takekoshi, K. .

JOURNAL OF NEUROENDOCRINOLOGY, 2007, 19 (08) :621-631

[5] 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside inhibits proinflammatory response in glial cells:: A possible role of AMP-activated protein kinase [J].

Giri, S ;

Nath, N ;

Smith, B ;

Viollet, B ;

Singh, AK ;

Singh, I .

JOURNAL OF NEUROSCIENCE, 2004, 24 (02) :479-487

[6] Hydrogen peroxide induces loss of dopamine transporter activity: a calcium-dependent oxidative mechanism [J].

Huang, CL ;

Huang, NK ;

Shyue, SK ;

Chern, Y .

JOURNAL OF NEUROCHEMISTRY, 2003, 86 (05) :1247-1259

[7] Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease [J].

Hurley, FM ;

Costello, DJ ;

Sullivan, AM .

EXPERIMENTAL NEUROLOGY, 2004, 185 (02) :281-289

[8] Effects of Liver Hydrolysate on the Blood Glucose in Metabolic Syndrome Model Rats (SHR/NDmcr-cp) [J].

Inoue, Naonori ;

Hidaka, Shuji ;

Miura, Naoyoshi ;

Yamada, Kotaro ;

Fukahori, Masahiro ;

Maruyama, Masugi ;

Kawahara, Satoshi ;

Ohta, Kazuyoshi ;

Muguruma, Michio .

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2013, 133 (01) :117-123

[9] Involvement of interferon-γ in microglial-mediated loss of dopaminergic neurons [J].

Mount, Matthew P. ;

Lira, Arman ;

Grimes, David ;

Smith, Patrice D. ;

Faucher, Sylvie ;

Slack, Ruth ;

Anisman, Hymie ;

Hayley, Shawn ;

Park, David S. .

JOURNAL OF NEUROSCIENCE, 2007, 27 (12) :3328-3337

[10] Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors [J].

Nader, Joelle ;

Rapino, Cinzia ;

Gennequin, Benjamin ;

Chavant, Francois ;

Francheteau, Maureen ;

Makriyannis, Alexandros ;

Duranti, Andrea ;

Maccarrone, Mauro ;

Solinas, Marcello ;

Thiriet, Nathalie .

NEUROPHARMACOLOGY, 2014, 87 :214-221

← 1 2 →